Precision medicine oncology company IDEAYA Biosciences Inc (Nasdaq: IDYA) announced on Monday that it has nominated IDE034, a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (BsADC), as a development candidate.
This follows the exercise of an exclusive worldwide licensing option from Biocytogen Pharmaceuticals (Beijing) Co, Ltd (HKEX: 02315).
IDEAYA plans to file an Investigational New Drug (IND) application with the FDA in 2025 to commence clinical evaluation.
IDE034, designed for potential monotherapy and combination use with IDEAYA's PARG inhibitor IDE161, targets solid tumours including lung and colorectal, as well as head and neck cancers, where B7H3/PTK7 co-expression rates are approximately 30%, 46% and 27%, respectively. IDEAYA will make up to USD406.5m in payments to Biocytogen, covering development milestones and royalties.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval